Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Objective With a vaccine effectiveness of 95% for preventing coronavirus disease 2019 (COVID‐19), Pfizer‐BioNTech BNT162b2 (BNT162b2) was the first vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) to be approved. However, immunosuppressive therapy was an exclusion criteri...

Full description

Bibliographic Details
Main Authors: Christian Ammitzbøll, Lars Erik Bartels, Jakob Bøgh Andersen, Signe Risbøl Vils, Clara Elbæk Mistegård, Anders Dahl Johannsen, Marie‐Louise From Hermansen, Marianne Kragh Thomsen, Christian Erikstrup, Ellen‐Margrethe Hauge, Anne Troldborg
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11299

Internet

https://doi.org/10.1002/acr2.11299

Similar Items